Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lexaria Bioscience Corp
(NQ:
LEXX
)
3.430
+0.020 (+0.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexaria Bioscience Corp
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology
Today 9:50 EDT
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology
Today 9:50 EDT
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs
May 06, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs
May 06, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
April 16, 2024
Via
ACCESSWIRE
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
May 06, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agreement
May 01, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agreement
May 01, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Awarded New Patents
April 02, 2024
Lexaria receives new patents in the fields of epilepsy and anti-viral agents
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Awarded New Patents
April 02, 2024
Via
ACCESSWIRE
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
April 30, 2024
Via
ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval
April 22, 2024
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval
April 22, 2024
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH
April 16, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH
April 16, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Global Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies for 2024
April 16, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment
April 11, 2024
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment
April 11, 2024
Via
CannabisNewsWire
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Focusing on ‘Overwhelming Interest’ for GLP-1 Applications of DehydraTECH(TM)
March 28, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires Contract Research Organization to Perform Important GLP-1 Human Pilot Study
March 25, 2024
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires Contract Research Organization to Perform Important GLP-1 Human Pilot Study
March 25, 2024
Via
CannabisNewsWire
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO to Present at the Upcoming 14th Annual LD Micro Invitational
March 21, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Achieves 7% Weight Loss; Sets Stage for 8-week Diabetes and Weight Loss Animal Study
March 21, 2024
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Huge 2024 Milestone with FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
March 18, 2024
Via
Investor Brand Network
Exposures
Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
March 14, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
March 14, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
March 14, 2024
Via
ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth
March 08, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth
March 08, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO for Second DehydraTECH-Powered GLP-1 Human Pilot Study
March 07, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.